Protagenic Therapeutics, Inc.
PTIX
$0.49
$0.1128.95%
OTC PK
| 09/30/2025 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | 3.23% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | -7.82% | ||||
| Operating Income | 7.82% | ||||
| Income Before Tax | 82.81% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | 82.81% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | 82.81% | ||||
| EBIT | 7.82% | ||||
| EBITDA | 7.90% | ||||
| EPS Basic | 65.59% | ||||
| Normalized Basic EPS | 65.60% | ||||
| EPS Diluted | 65.59% | ||||
| Normalized Diluted EPS | 65.60% | ||||
| Average Basic Shares Outstanding | -50.03% | ||||
| Average Diluted Shares Outstanding | -50.03% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||